Featured Articles

1. RWE Is Not Optional, It's Essential 8/25/2025

   UCB Head of Medical Strategy, Bone Health, Jennifer Timoshanko explains why RWE is a valuable alternative to RCTs and shares best practices for collecting it.

2. Vegas To Tokyo: How Global Tech Conferences Shape Healthcare's Future 8/19/2025

   Google's Shweta Maniar writes about what she's learned traveling to conferences across the planet to talk about the convergence of healthcare, drug development, and digital technology.

3. The Future Of Psychedelic-Inspired Therapeutics: No-Trip Neuroplastogens 8/14/2025

   Non-hallucinogenic neuroplastogens offer benefits over classical psychedelics, including simpler delivery, stronger IP protection, and patient tolerability, writes Enveric Biosciences CEO Joseph Tucker, Ph.D.

4. Staying Ahead In A Rapidly Evolving Obesity Market 8/11/2025

   As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win market share in an increasingly crowded therapeutic area.

5. Helping Quiet Life Science Leaders Be Seen, Heard, and Valued 8/5/2025

   Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to influential within their organizations.

6. From Scientific Discovery To Next Generation Treatments For Obesity 7/31/2025

   Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver products that improve upon currently available treatments for obesity.

7. What Life Sciences Companies Can Learn From BMW and Volkswagen 7/30/2025

   Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new products, write Noël Theodosiou and Patrick O. Gee.

8. Open Science And A Robust IP Strategy: Life Sciences Can Do Both 7/28/2025

   By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without risking exclusive rights over valuable assets, writes Richard Gold.

9. All Of Us Need To Be Rooting For The FDA 7/23/2025

   In light of FDA leadership changes and operational updates, FDA Matters' Steven Grossman asks us all to slow down and consider why we should be cheering on, not tearing down, the present-day FDA.

10. Why So Many Biotech Launches Miss Expectations, And How To Fix It 7/18/2025

    More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real world impacts, among other things, can help, explains Bennett Smith.